Literature DB >> 8555489

The promoter and 5' flanking sequences controlling human B29 gene expression.

A A Thompson1, W J Wood, M J Gilly, M A Damore, S A Omori, R Wall.   

Abstract

The product of the B-cell-specific B29 gene (B29, Ig beta, CD79b) is essential for Ig-mediated B-cell activation via the B-cell antigen receptor complex (BCR) on human and murine B lymphocytes. To better understand the regulation of this pivotal gene, we have analyzed the human genomic DNA sequence upstream of the B29 ATG start codon for transcriptional control activity. The human B29 gene lacks either a TATA or a CAAT box and transcription is initiated at multiple sites. The minimal promoter of the human B29 gene is contained within a 193-bp region 5' of these multiple start sites. This minimal promoter exhibits B-cell-specific activity and contains SP1, ETS, OCT, and IKAROS/LYF-1 transcription factor motifs. All these motifs are strikingly conserved in sequence and placement relative to the previously characterized murine B29 promoter. Additional upstream gene segments dramatically affected B29 minimal promoter activity. A newly identified motif called the B29 conserved sequence (BCS), found upstream of both human and murine B29 promoters, appears to stimulate B29 transcription through a novel mechanism. A single BCS had little effect either on the minimal B29 promoter or on a heterologous promoter. Instead, the BCS stimulated transcription by counteracting 5' negative regulatory DNA sequences that block the activity of the B29 minimal promoter in its absence. These findings indicate that B29 gene expression is controlled by the complex interplay of positive and negative regulatory elements.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8555489

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  An RNA-independent linkage of noncoding transcription to long-range enhancer function.

Authors:  Eung Jae Yoo; Nancy E Cooke; Stephen A Liebhaber
Journal:  Mol Cell Biol       Date:  2012-03-19       Impact factor: 4.272

2.  Distinct factors regulate the murine RAG-2 promoter in B- and T-cell lines.

Authors:  J Lauring; M S Schlissel
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

3.  Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.

Authors:  Blythe D Sather; Byoung Y Ryu; Brigid V Stirling; Mikhail Garibov; Hannah M Kerns; Stéphanie Humblet-Baron; Alexander Astrakhan; David J Rawlings
Journal:  Mol Ther       Date:  2010-12-07       Impact factor: 11.454

4.  CmC(A/T)GG DNA methylation in mature B cell lymphoma gene silencing.

Authors:  C S Malone; M D Miner; J R Doerr; J P Jackson; S E Jacobsen; R Wall; M Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

5.  B29 gene silencing in pituitary cells is regulated by its 3' enhancer.

Authors:  Cindy S Malone; Ali I Kuraishy; Francesca M Fike; Ruchika G Loya; Minil R Mikkili; Michael A Teitell; Randolph Wall
Journal:  J Mol Biol       Date:  2006-07-28       Impact factor: 5.469

6.  Silencer elements controlling the B29 (Igbeta) promoter are neither promoter- nor cell-type-specific.

Authors:  C S Malone; S A Omori; R Wall
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  Structural and functional analysis of the HSP90AA1 gene: distribution of polymorphisms among sheep with different responses to scrapie.

Authors:  Ane Marcos-Carcavilla; Jorge H Calvo; Carmen González; Katayoun Moazami-Goudarzi; Pascal Laurent; Maud Bertaud; Hélène Hayes; Anne E Beattie; Carmen Serrano; Jaber Lyahyai; Inmaculada Martín-Burriel; Magdalena Serrano
Journal:  Cell Stress Chaperones       Date:  2008-02-05       Impact factor: 3.667

8.  Bystander gene activation by a locus control region.

Authors:  Isabela Cajiao; Aiwen Zhang; Eung Jae Yoo; Nancy E Cooke; Stephen A Liebhaber
Journal:  EMBO J       Date:  2004-09-09       Impact factor: 11.598

9.  B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.

Authors:  Hannah M Kerns; Byoung Y Ryu; Brigid V Stirling; Blythe D Sather; Alexander Astrakhan; Stephanie Humblet-Baron; Denny Liggitt; David J Rawlings
Journal:  Blood       Date:  2010-01-21       Impact factor: 22.113

10.  The B29 (immunoglobulin beta-chain) gene is a genetic target for early B-cell factor.

Authors:  P Akerblad; M Rosberg; T Leanderson; M Sigvardsson
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.